PARTNER 3
2019
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
In 1,000 patients with severe AS at low surgical risk, TAVR with the SAPIEN 3 valve reduced death, stroke or rehospitalisation at one year versus surgical AVR.
Result
Efficacy: Death, stroke, rehospitalisationHR 0.54
Below 1 favours TAVR with the SAPIEN 3 valve, above 1 favours surgical AVR.
- Absolute difference
- 6.6 points
The absolute difference is derived from the event rates.
- Subtopic
- TAVR
- Design
- RCT, 1 yr (non-inferiority + superiority)
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2025 VHDACC/AHA 2020 VHD
- Source
- Mack MJ, et al. N Engl J Med. 2019;380(18):1695-1705.doi 10.1056/NEJMoa1814052
Discussion & critique
Driven largely by rehospitalisation. Longer-term durability data still maturing, relevant for younger, low-risk patients with decades of remaining life.